5 Results for "

FXR target genes

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "FXR target genes" in MCE Product Catalog:

1
Rebaudioside D
Rebaudioside D
0 Images
1 Cited Publications
Cat. No.: HY-N0468
CAS No.: 63279-13-0
Category:  

other families Terpenoids Metabolic Disease Diterpenoids Plants Disease Research Fields Sweeteners Food Research

Target:  

FXR Acetyl-CoA Carboxylase

Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
loading...
    loading...
View All Sizes
Isochenodeoxycholic acid
Isochenodeoxycholic acid
0 Images
Cat. No.: HY-N4067
CAS No.: 566-24-5
Synonyms: isoCDCA
Category:  

Natural Products

Target:  

FXR Endogenous Metabolite

Isochenodeoxycholic acid (isoCDCA) is a FXR agonist. Isochenodeoxycholic acid activates the activity of FXR and induces the mRNA expression of FXR target genes (Ostβ and Kng1). Isochenodeoxycholic acid serves as a substrate for the liver class I ADH γγ isozyme-mediated 3β-dehydrogenation reaction .
loading...
    loading...
View All Sizes
Rebaudioside D (Standard)
Rebaudioside D (Standard)
0 Images
Cat. No.: HY-N0468R
CAS No.: 63279-13-0
Category:  

other families Terpenoids Diterpenoids Plants

Target:  

Reference Standards Acetyl-CoA Carboxylase FXR

Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
loading...
    loading...
View All Sizes
SJYHJ-026
SJYHJ-026
0 Images
Cat. No.: HY-169264
Target:  

PROTACs Pregnane X Receptor (PXR)

Research Areas:  

Cancer

SJYHJ-026 is a PROTAC degrader targeting PXR, with a DC50 of 86.6 nM in SNU-C4 HiBiT-PXR KI cells. SJYHJ-026 shows higher selectivity for PXR over CAR, VDR, FXR, LXRα and LXRβ, and can bind to VHL to form a PXR-SJYHJ-026-VHL complex, inducing proteasomal degradation of PXR. SJYHJ-026 blocks agonist-induced PXR-mediated gene expression (including CYP3A4) and reduces basal PXR activity at the CYP3A4 promoter. SJYHJ-026 can be used for the research of colorectal cancer .
loading...
    loading...
View All Sizes
PROTAC PXR degrader-1
PROTAC PXR degrader-1
0 Images
Cat. No.: HY-169279
Target:  

PROTACs Pregnane X Receptor (PXR)

Research Areas:  

Cancer

PROTAC PXR degrader-1 is a PROTAC degrader targeting PXR, with a DC50 value of 49.8 nM in SNU-C4 3xFLAG-PXR KI cells. PROTAC PXR degrader-1 exhibits selectivity towards CAR, VDR, FXR, LXRα and LXRβ. PROTAC PXR degrader-1 induces the formation of a ternary complex with PXR and VHL, triggering proteasomal degradation of PXR. PROTAC PXR degrader-1 reduces both agonist-induced and basal PXR-mediated CYP3A4 promoter activation, and decreases the expression of endogenous CYP3A4 gene in cancer cells. PROTAC PXR degrader-1 enhances the cytotoxic effect of paclitaxel on cancer cells. PROTAC PXR degrader-1 can be used for the research of colorectal cancer .
loading...
    loading...
View All Sizes
Assay Types